Doug Maffei | Senior Director of Investor Relations |
Daniel O'Day | Chairman and Chief Executive Officer |
Andrew Dickinson | Chief Financial Officer |
Johanna Mercier | Chief Commercial Officer |
Merdad Parsey | Chief Medical Officer |
Christi Shaw | Chief Executive Officer of Kite |
Diana Brainard | SVP and Head of HIV and Emerging Viruses Therapeutic Area |
Michael Yee | Jefferies |
Cory Kasimov | JP Morgan |
Brian Abrahams | RBC Capital Markets |
Geoff Meacham | Bank of America |
Geoffrey Porges | SVB Leerink |
Matthew Harrison | Morgan Stanley |
Umer Raffat | Evercore |
Alethia Young | Cantor Fitzgerald |
Mohit Bansal | Citigroup |
Robyn Karnauskas | SunTrust |
Salim Syed | Mizuho |
Tyler Van Buren | Piper Sandler |
Phil Nadeau | Cowen and Company |
Ladies and gentlemen, thank you for standing by. And welcome to the First Quarter 2020 Gilead Sciences Earnings Conference Call. At this time, all participants are in a listen-only mode [Operator Instructions]. Please be advised that today’s conference is being recorded [Operator Instructions].
It is now my pleasure to introduce Senior Director of Investor Relations, Doug Maffei.